Ustekinumab in the therapy of chronic plaque psoriasis

Jenna L O’Neill, Robert E KalbState University of New York at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USAAbstract: Psoriasis is a chronic inflammatory disorder characterized by T cell dysregulation and a chronic inflammatory infiltrate within...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jenna L O’Neill, Robert E Kalb
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://doaj.org/article/4b41c48fa8894b93843f32c8ef6c87df
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4b41c48fa8894b93843f32c8ef6c87df
record_format dspace
spelling oai:doaj.org-article:4b41c48fa8894b93843f32c8ef6c87df2021-12-02T01:34:46ZUstekinumab in the therapy of chronic plaque psoriasis1177-54751177-5491https://doaj.org/article/4b41c48fa8894b93843f32c8ef6c87df2009-03-01T00:00:00Zhttp://www.dovepress.com/ustekinumab-in-the-therapy-of-chronic-plaque-psoriasis-a2992https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Jenna L O’Neill, Robert E KalbState University of New York at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USAAbstract: Psoriasis is a chronic inflammatory disorder characterized by T cell dysregulation and a chronic inflammatory infiltrate within the epidermis. Several cytokines play an important role in the pathogenesis of psoriasis, including interleukin-12 (IL-12) and IL-23. These cytokines act via induction of pro-inflammatory cytokines which promote chronic inflammation and auto-reactivity. Ustekinumab is a fully human monoclonal antibody against the common p40 subunit of IL-12 and IL-23. Two randomized, double-blind, placebo-controlled trials of ustekinumab have demonstrated significant and prolonged efficacy in the treatment of plaque psoriasis. Adverse events were generally similar across treatment and control groups. Studies are ongoing to assess the long term safety and efficacy profiles of ustekinumab.Keywords: ustekinumab, psoriasis, plaque Jenna L O’NeillRobert E KalbDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 159-168 (2009)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Jenna L O’Neill
Robert E Kalb
Ustekinumab in the therapy of chronic plaque psoriasis
description Jenna L O’Neill, Robert E KalbState University of New York at Buffalo, School of Medicine and Biomedical Sciences, Department of Dermatology, NY, USAAbstract: Psoriasis is a chronic inflammatory disorder characterized by T cell dysregulation and a chronic inflammatory infiltrate within the epidermis. Several cytokines play an important role in the pathogenesis of psoriasis, including interleukin-12 (IL-12) and IL-23. These cytokines act via induction of pro-inflammatory cytokines which promote chronic inflammation and auto-reactivity. Ustekinumab is a fully human monoclonal antibody against the common p40 subunit of IL-12 and IL-23. Two randomized, double-blind, placebo-controlled trials of ustekinumab have demonstrated significant and prolonged efficacy in the treatment of plaque psoriasis. Adverse events were generally similar across treatment and control groups. Studies are ongoing to assess the long term safety and efficacy profiles of ustekinumab.Keywords: ustekinumab, psoriasis, plaque
format article
author Jenna L O’Neill
Robert E Kalb
author_facet Jenna L O’Neill
Robert E Kalb
author_sort Jenna L O’Neill
title Ustekinumab in the therapy of chronic plaque psoriasis
title_short Ustekinumab in the therapy of chronic plaque psoriasis
title_full Ustekinumab in the therapy of chronic plaque psoriasis
title_fullStr Ustekinumab in the therapy of chronic plaque psoriasis
title_full_unstemmed Ustekinumab in the therapy of chronic plaque psoriasis
title_sort ustekinumab in the therapy of chronic plaque psoriasis
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/4b41c48fa8894b93843f32c8ef6c87df
work_keys_str_mv AT jennaloamprsquoneill ustekinumabinthetherapyofchronicplaquepsoriasis
AT robertekalb ustekinumabinthetherapyofchronicplaquepsoriasis
_version_ 1718402955771641856